Lyell Non Current Liabilities Total from 2010 to 2024
| LYEL Stock | USD 0.95 0.03 3.26% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 60.6 M | Current Value 87.2 M | Quarterly Volatility 25.3 M |
Check Lyell Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyell Immunopharma's main balance sheet or income statement drivers, such as Net Interest Income of 24.6 M, Interest Income of 24.6 M or Depreciation And Amortization of 13.9 M, as well as many indicators such as Price To Sales Ratio of 2.4 K, Dividend Yield of 0.0 or PTB Ratio of 0.71. Lyell financial statements analysis is a perfect complement when working with Lyell Immunopharma Valuation or Volatility modules.
Lyell | Non Current Liabilities Total |
Latest Lyell Immunopharma's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Lyell Immunopharma over the last few years. It is Lyell Immunopharma's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyell Immunopharma's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Lyell Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 117,450,264 | |
| Geometric Mean | 114,189,921 | |
| Coefficient Of Variation | 21.56 | |
| Mean Deviation | 18,312,378 | |
| Median | 125,531,000 | |
| Standard Deviation | 25,319,484 | |
| Sample Variance | 641.1T | |
| Range | 90.3M | |
| R-Value | (0.51) | |
| Mean Square Error | 513.2T | |
| R-Squared | 0.26 | |
| Significance | 0.05 | |
| Slope | (2,868,394) | |
| Total Sum of Squares | 8975.1T |
Lyell Non Current Liabilities Total History
About Lyell Immunopharma Financial Statements
Lyell Immunopharma investors utilize fundamental indicators, such as Non Current Liabilities Total, to predict how Lyell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 60.6 M | 87.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lyell Immunopharma Correlation against competitors. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.